Innate Pharma Total Revenue

Innate Pharma (IPHA) currently reports a total revenue of $12M as of December 2025. That compares with $69M in the prior-year period — down 82.0% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Innate Pharma's total revenue history and peer comparisons.

Innate Pharma's total revenue decreased from $69M to $12M — a 82.0% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Innate Pharma's total revenue of $12M is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Innate Pharma reported $12M in total revenue as of December 2025. That compares with $69M in the prior-year period — down 82.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $12M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Innate Pharma, and consider following IPHA for alerts when major investors trade the stock.